Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson(Vanderbilt University), Joseph I. Clark(Loyola University Medical Center), Carolin Bender(Heidelberg University), Alexander M. Menzies(The University of Sydney), Patrick A. Ott(Dana-Farber Cancer Institute), Igor Puzanov(Vanderbilt University Medical Center), Donald P. Lawrence(Massachusetts General Hospital), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Tejaswi Mudigonda(Vanderbilt University Medical Center), Elizabeth I. Buchbinder(Dana-Farber Cancer Institute), Jessica C. Hassel(National Center for Tumor Diseases), Georgina V. Long(Westmead Hospital), Jeffrey A. Sosman(Palmetto Hematology Oncology), Matteo S. Carlino(The University of Sydney), Kristen Spencer(Rutgers Cancer Institute), Howard L. Kaufman(Rutgers, The State University of New Jersey), Fei Ye(UPMC Hillman Cancer Center), Jenny Lee(Blacktown & Mount Druitt Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute), Janice M. Mehnert(Rutgers Cancer Institute of New Jersey), Alexander Guminski(The University of Sydney)
Cited by 656
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k